Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on July 10, 2007
JNCI Journal of the National Cancer Institute 2007 99(14):1064-1065; doi:10.1093/jnci/djm075
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
99/14/1064    most recent
djm075v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Inconsistency of HER2 Test Raises Questions

Rabiya S. Tuma

The first 150 words of the full text of this article appear below.

The tests that determine who gets the powerful breast cancer drug trastuzumab (Herceptin) may not be as reliable as previously thought, researchers reported at the annual meeting of the American Society of Clinical Oncology. That means some women who should be getting trastuzumab treatment are not, while other women who will not benefit are unnecessarily exposed to a drug that can cause heart problems.

"This is a very big deal," said Larry Norton, M.D., deputy physician in chief for breast cancer programs at Memorial Sloan-Kettering Cancer Center, who was not involved with either of the new studies that uncovered the problem.

Trastuzumab is often cited as the one of the few successful examples of personalized medicine, because only patients whose tumors express the HER2/neu protein are given the drug. It has been shown to reduce the risk of relapse and improve overall survival in those patients.

Currently, two tests are . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
R A Walker
Immunohistochemical markers as predictive tools for breast cancer
J. Clin. Pathol., June 1, 2008; 61(6): 689 - 696.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Di Palma, N Collins, M Bilous, A Sapino, M Mottolese, N Kapranos, F Schmitt, and J Isola
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer
J. Clin. Pathol., June 1, 2008; 61(6): 757 - 760.
[Abstract] [Full Text] [PDF]